Reivindicaciones

1. A method for the treatment of endotoxic shock in mammals characterised in that it comprises administration of an effective amount of an agent that inhibits the production of tumor necrosis factor (TNF) in a pharmaceutically acceptable vehicle. 2. A method for the treatment of endotoxic shock in mammals according to claim 1, characterised in that the inhibitory agent is the vasoactive intestinal peptide (VIP) or a fragment thereofor an analogue derived therefrom. 3. A method for the treatment of endotoxic shock in mammals according to claim 1, characterised in that the inhibitory agent is the peptide activating hypofissiary adenylate cyclase (PACAP) or a fragment thereof or an analogue derived therefrom. 4. A method for the treatment of endotoxic shock in mammals characterised in that it comprises the administration of an effective amount of an agent that inhibits the production of interleukin 6 (IL-6) in a pharmaceutically acceptable vehicle. 5. A method for the treatment of endotoxic shock in mammals according to claim 4, characterised in that the inhibitory agent is the vasoactive intestinal peptide (VIP) or a fragment thereof or an analogue derived therefrom. 6. A method for the treatment of endotoxic shock in mammals, according to claim 4, characterised in that the inhibitory agent is the peptide activating hypofissiary adenylate cyclase (PACAP) or a fragment thereof or an analogue derived therefrom.